SLC5A2 and type 2 diabetes mellitus: The primary care in T2DM is pharmacological, especially considering the beneficial effects of new antidiabetic classes of drugs (GLP-1R agonists and SGLT2 inhibitors) on the primary and secondary prevention of cardiovascular and kidney diseases.